Pliant Therapeutics (PLRX) EBT (2019 - 2026)

Pliant Therapeutics (PLRX) has reported EBT for 8 consecutive years, with -$22.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT rose 48.33% year-over-year to -$22.4 million in Q2 2026; TTM through Jun 2026 was -$92.5 million, a 56.09% increase from a year earlier, with the FY2025 full-year figure at -$147.5 million, up 29.86% from the prior year.
• EBT was -$22.4 million for Q2 2026 at Pliant Therapeutics, down from -$22.1 million in the prior quarter.
• Over five years, EBT peaked at -$21.7 million in Q4 2025 and troughed at -$61.6 million in Q2 2024.
• A 5-year average of -$39.6 million and a median of -$41.3 million in 2023 frame the typical range for EBT.
• Across the five-year window, EBT tumbled 61.19% in 2023 and surged 63.11% in 2026, its largest moves.
• Over 5 years, EBT stood at -$30.8 million in 2022, then plunged by 33.5% to -$41.1 million in 2023, then retreated by 20.98% to -$49.7 million in 2024, then soared by 56.27% to -$21.7 million in 2025, then fell by 2.86% to -$22.4 million in 2026.
• The last three EBT figures came in at -$22.4 million (Q2 2026), -$22.1 million (Q1 2026), and -$21.7 million (Q4 2025), per Business Quant data.